TY - JOUR
T1 - Role of palmitoylethanolamide (PEA) in depression
T2 - Translational evidence: Special Section on “Translational and Neuroscience Studies in Affective Disorders”. Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders
AU - De Gregorio, Danilo
AU - Manchia, Mirko
AU - Carpiniello, Bernardo
AU - Valtorta, Flavia
AU - Nobile, Maria
AU - Gobbi, Gabriella
AU - Comai, Stefano
N1 - Funding Information:
Dr. Danilo De Gregorio is supported by a post-doctoral fellowship from the Fonds de la recherché du Quebec en Santé (FRQS). Dr. Mirko Manchia is supported by a grant funded by Fondazione di Sardegna and Regione Autonoma della Sardegna, Italy, L.R. 7/2007, year 2016 – DGR 28/21 del 17.05.2015. Dr. Stefano Comai is supported in part by a 2017 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation .
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Background: Antidepressants have a low rate of response paired with a delayed onset of action. Translational studies are thus seeking for novel targets for antidepressant drug development. Preclinical evidence has demonstrated that the endocannabinoid system plays an important role in mood and stress response, even if drugs targeting this system have not yet become available for clinical use. The dietary supplement N-Palmitoylethanolamide (PEA) is a fatty acid amide belonging to the endocannabinoid system with potential antidepressant properties. Methods: We performed a bibliographic search to review current knowledge on the potential antidepressant effects of PEA and its underlying mechanism of action. Results: PEA targets not only the peroxisome proliferator-activated receptor-alpha (PPAR-α), but also the endocannabinoid system, binding the G-protein-coupled receptor 55, a non-CB1/CB2 cannabinoid receptor, and also the CB1/CB2 receptors, although with a weak affinity. Preclinical studies have shown antidepressant activity of PEA in animal paradigms of depression and of depression associated with neuropathic pain and traumatic brain injury. In a translational perspective, PEA is increased in stress conditions, and a randomized, double-blind study in depressed patients indicated a fast-antidepressant action of PEA when associated with citalopram. Limitations: There are still limited preclinical and clinical studies investigating the effect of PEA upon the endocannabinoid system and its potential as antidepressant. Conclusions: PEA has potential antidepressant effects alone or in combinations with other classes of antidepressants. Future studies in depressed patients are needed to confirm the mood-modulating properties of PEA and its role as a biomarker of depression.
AB - Background: Antidepressants have a low rate of response paired with a delayed onset of action. Translational studies are thus seeking for novel targets for antidepressant drug development. Preclinical evidence has demonstrated that the endocannabinoid system plays an important role in mood and stress response, even if drugs targeting this system have not yet become available for clinical use. The dietary supplement N-Palmitoylethanolamide (PEA) is a fatty acid amide belonging to the endocannabinoid system with potential antidepressant properties. Methods: We performed a bibliographic search to review current knowledge on the potential antidepressant effects of PEA and its underlying mechanism of action. Results: PEA targets not only the peroxisome proliferator-activated receptor-alpha (PPAR-α), but also the endocannabinoid system, binding the G-protein-coupled receptor 55, a non-CB1/CB2 cannabinoid receptor, and also the CB1/CB2 receptors, although with a weak affinity. Preclinical studies have shown antidepressant activity of PEA in animal paradigms of depression and of depression associated with neuropathic pain and traumatic brain injury. In a translational perspective, PEA is increased in stress conditions, and a randomized, double-blind study in depressed patients indicated a fast-antidepressant action of PEA when associated with citalopram. Limitations: There are still limited preclinical and clinical studies investigating the effect of PEA upon the endocannabinoid system and its potential as antidepressant. Conclusions: PEA has potential antidepressant effects alone or in combinations with other classes of antidepressants. Future studies in depressed patients are needed to confirm the mood-modulating properties of PEA and its role as a biomarker of depression.
UR - http://www.scopus.com/inward/record.url?scp=85055755585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055755585&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2018.10.117
DO - 10.1016/j.jad.2018.10.117
M3 - Review article
C2 - 30391203
AN - SCOPUS:85055755585
SN - 0165-0327
VL - 255
SP - 195
EP - 200
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -